Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions
- PMID: 28902785
- PMCID: PMC5679236
- DOI: 10.1097/MPA.0000000000000898
Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions
Abstract
Objectives: Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival.
Methods: Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models.
Results: Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87).
Conclusions: Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
Conflict of interest statement
Figures



Similar articles
-
Nutritional and immune impairments and their effects on outcomes in early pancreatic cancer patients undergoing pancreatoduodenectomy.Clin Nutr. 2020 Nov;39(11):3385-3394. doi: 10.1016/j.clnu.2020.02.029. Epub 2020 Mar 6. Clin Nutr. 2020. PMID: 32184025 Clinical Trial.
-
Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.BMC Cancer. 2009 Jul 28;9:255. doi: 10.1186/1471-2407-9-255. BMC Cancer. 2009. PMID: 19635171 Free PMC article.
-
The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy.Surg Today. 2017 Nov;47(11):1361-1371. doi: 10.1007/s00595-017-1522-x. Epub 2017 Apr 18. Surg Today. 2017. PMID: 28421348
-
Cachexia and pancreatic cancer: are there treatment options?World J Gastroenterol. 2014 Jul 28;20(28):9361-73. doi: 10.3748/wjg.v20.i28.9361. World J Gastroenterol. 2014. PMID: 25071331 Free PMC article. Review.
-
The Interplay Among Pancreatic Cancer, Cachexia, Body Composition, and Diabetes.Hematol Oncol Clin North Am. 2022 Oct;36(5):897-910. doi: 10.1016/j.hoc.2022.07.001. Epub 2022 Sep 23. Hematol Oncol Clin North Am. 2022. PMID: 36154783 Review.
Cited by
-
Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):358-368. doi: 10.1002/jcsm.12251. Epub 2018 Jan 7. J Cachexia Sarcopenia Muscle. 2018. PMID: 29316343 Free PMC article.
-
Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma.J Gastrointest Cancer. 2021 Mar;52(1):160-168. doi: 10.1007/s12029-020-00378-z. J Gastrointest Cancer. 2021. PMID: 32077005
-
Exploring and validating the clinical risk factors for pancreatic cancer in chronic pancreatitis patients using electronic medical records datasets: three cohorts comprising 2,960 patients.Transl Cancer Res. 2020 Feb;9(2):629-638. doi: 10.21037/tcr.2019.11.49. Transl Cancer Res. 2020. PMID: 35117408 Free PMC article.
-
Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer.Cancers (Basel). 2023 Sep 1;15(17):4368. doi: 10.3390/cancers15174368. Cancers (Basel). 2023. PMID: 37686641 Free PMC article.
-
Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis.Adv Nutr. 2024 Sep;15(9):100282. doi: 10.1016/j.advnut.2024.100282. Epub 2024 Aug 8. Adv Nutr. 2024. PMID: 39127425 Free PMC article.
References
-
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
-
- Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495. - PubMed
-
- Ozola Zalite I, Zykus R, Francisco Gonzalez M, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology. 2015;15:19–24. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical